Literature DB >> 11344014

Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson's disease and correlates with PET

P K. Pal1, C S. Lee, A Samii, M Schulzer, A J. Stoessl, E K. Mak, J Wudel, T Dobko, J K.C. Tsui.   

Abstract

We explored an objective method of measuring clinical severity of Parkinson's disease. Eighty-six patients with PD and 136 healthy subjects were studied. We serially carried out four types of finger tapping (FT) using a computerized drum machine: (i) repetitive one-finger tapping with an index-finger (F1K1); (ii) one-finger tapping on two keys separated by 20cm (F1K2); (iii) alternate tapping with index and middle fingers on two adjacent keys (F2K2); and (iv) F2K2 with contralateral activation (aF2K2). Analyses on FT included: (i) age and gender effects in healthy volunteers and Parkinson's disease; (ii) comparison between Parkinson patients and controls of similar age distribution; (iii) correlation with the Purdue Pegboard and Modified Columbia Scale in Disease; and (iv) in a subset of patients in whom PET scans were performed (n=30), correlation with 18F-DOPA uptake constant (Ki). In healthy subjects, there was a negative age effect on FT scores and a gender effect, with males scoring higher than females. All FT scores were significantly lower in the Parkinson patients, correlated with Purdue Peg Board, and inversely with the duration of illness, and with the Modified Columbia Scale. The 18F-DOPA Ki correlated significantly with aF2K2 (p=0.024), less so with PPB (p=0.038), but not with the Modified Columbia Scale. We conclude that alternating two-finger tapping with contralateral hand activation is a simple, objective test for measuring the severity of Parkinson's disease.

Entities:  

Year:  2001        PMID: 11344014     DOI: 10.1016/s1353-8020(00)00048-1

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  19 in total

1.  (18)F-DOPA PET with and without MRI fusion, a receiver operator characteristics comparison.

Authors:  Aaron F Struck; Lance T Hall; Joanna E Kusmirek; Catherine L Gallagher; John M Floberg; Christine J Jaskowiak; Scott B Perlman
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-10-15

2.  Different response to instrumental tests in relation to cognitive demand after dopaminergic stimulation in previously treated patients with Parkinson's disease.

Authors:  Thomas Müller; Ali Harati
Journal:  J Neural Transm (Vienna)       Date:  2020-02-01       Impact factor: 3.575

3.  Improved efficacy of temporally non-regular deep brain stimulation in Parkinson's disease.

Authors:  David T Brocker; Brandon D Swan; Dennis A Turner; Robert E Gross; Stephen B Tatter; Mandy Miller Koop; Helen Bronte-Stewart; Warren M Grill
Journal:  Exp Neurol       Date:  2012-09-27       Impact factor: 5.330

4.  Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease.

Authors:  S H Lee; M J Lee; C H Lyoo; H Cho; M S Lee
Journal:  J Neural Transm (Vienna)       Date:  2018-07-03       Impact factor: 3.575

5.  Sensitivity and specificity of the finger tapping task for the detection of psychogenic movement disorders.

Authors:  Susan Criswell; Callen Sterling; Laura Swisher; Brad Evanoff; Brad A Racette
Journal:  Parkinsonism Relat Disord       Date:  2009-12-14       Impact factor: 4.891

6.  Diadochokinetic movements differ between patients with Parkinson's disease and controls.

Authors:  Thomas Müller; Ali Harati
Journal:  J Neural Transm (Vienna)       Date:  2009-11-10       Impact factor: 3.575

7.  An integrative model of Parkinson's disease treatment including levodopa pharmacokinetics, dopamine kinetics, basal ganglia neurotransmission and motor action throughout disease progression.

Authors:  Florence Véronneau-Veilleux; Philippe Robaey; Mauro Ursino; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-10-21       Impact factor: 2.745

8.  Supervised versus unsupervised technology-based levodopa monitoring in Parkinson's disease: an intrasubject comparison.

Authors:  Giovanna Lopane; Sabato Mellone; Mattia Corzani; Lorenzo Chiari; Pietro Cortelli; Giovanna Calandra-Buonaura; Manuela Contin
Journal:  J Neurol       Date:  2018-03-29       Impact factor: 4.849

9.  Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson's disease.

Authors:  Giovanna Calandra-Buonaura; Andrea Doria; Giovanna Lopane; Pietro Guaraldi; Sabina Capellari; Paolo Martinelli; Pietro Cortelli; Manuela Contin
Journal:  J Neurol       Date:  2015-11-14       Impact factor: 4.849

10.  Quantitative assessment of finger tapping characteristics in mild cognitive impairment, Alzheimer's disease, and Parkinson's disease.

Authors:  David R Roalf; Petra Rupert; Dawn Mechanic-Hamilton; Laura Brennan; John E Duda; Daniel Weintraub; John Q Trojanowski; David Wolk; Paul J Moberg
Journal:  J Neurol       Date:  2018-04-04       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.